Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCβI/MAPK pathways

Seung Hyun Kim, Jin Cheol Yoo, Tae Sung Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)2D3 that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evaluated the effects of nargenicin on cellular differentiation in a human myeloid leukemia HL-60 cell system. Nargenicin inhibited cell proliferation and induced HL-60 cell differentiation when administered in combination with 1,25-(OH)2D3 or ATRA. In addition, western blot analyses and kinase inhibitor studies demonstrated that nargenicin primarily enhanced leukemia cell differentiation via PKCβ1/MAPK pathways. The results of this study indicate that nargenicin has the ability to induce differentiation and suggest that it may be useful for the treatment of neoplastic diseases.

Original languageEnglish
Pages (from-to)1694-1701
Number of pages8
JournalBiochemical Pharmacology
Volume77
Issue number11
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

Actinobacteria
Calcitriol
HL-60 Cells
Tretinoin
Acute Myeloid Leukemia
Cell Differentiation
Leukemia
Nocardia
Myeloid Leukemia
Cell proliferation
Drug-Related Side Effects and Adverse Reactions
Drug Resistance
Pharmaceutical Preparations
Toxicity
Phosphotransferases
Western Blotting
Cell Proliferation
Anti-Bacterial Agents
Molecules

Keywords

  • 1,25-Dihydroxyvitamin D
  • All-trans retinoic acid
  • Cell differentiation
  • Mitogen-activated protein kinase
  • Nargenicin
  • Protein kinase C

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCβI/MAPK pathways. / Kim, Seung Hyun; Yoo, Jin Cheol; Kim, Tae Sung.

In: Biochemical Pharmacology, Vol. 77, No. 11, 01.06.2009, p. 1694-1701.

Research output: Contribution to journalArticle

@article{3581b95df72346a6b42df23e96b530ee,
title = "Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCβI/MAPK pathways",
abstract = "A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)2D3 that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evaluated the effects of nargenicin on cellular differentiation in a human myeloid leukemia HL-60 cell system. Nargenicin inhibited cell proliferation and induced HL-60 cell differentiation when administered in combination with 1,25-(OH)2D3 or ATRA. In addition, western blot analyses and kinase inhibitor studies demonstrated that nargenicin primarily enhanced leukemia cell differentiation via PKCβ1/MAPK pathways. The results of this study indicate that nargenicin has the ability to induce differentiation and suggest that it may be useful for the treatment of neoplastic diseases.",
keywords = "1,25-Dihydroxyvitamin D, All-trans retinoic acid, Cell differentiation, Mitogen-activated protein kinase, Nargenicin, Protein kinase C",
author = "Kim, {Seung Hyun} and Yoo, {Jin Cheol} and Kim, {Tae Sung}",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.bcp.2009.03.004",
language = "English",
volume = "77",
pages = "1694--1701",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Nargenicin enhances 1,25-dihydroxyvitamin D3- and all-trans retinoic acid-induced leukemia cell differentiation via PKCβI/MAPK pathways

AU - Kim, Seung Hyun

AU - Yoo, Jin Cheol

AU - Kim, Tae Sung

PY - 2009/6/1

Y1 - 2009/6/1

N2 - A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)2D3 that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evaluated the effects of nargenicin on cellular differentiation in a human myeloid leukemia HL-60 cell system. Nargenicin inhibited cell proliferation and induced HL-60 cell differentiation when administered in combination with 1,25-(OH)2D3 or ATRA. In addition, western blot analyses and kinase inhibitor studies demonstrated that nargenicin primarily enhanced leukemia cell differentiation via PKCβ1/MAPK pathways. The results of this study indicate that nargenicin has the ability to induce differentiation and suggest that it may be useful for the treatment of neoplastic diseases.

AB - A major goal in the treatment of acute myeloid leukemia (AML) is to achieve terminal differentiation and prevent drug resistance and side effects. Combined treatment with low doses of ATRA or 1,25-(OH)2D3 that do not induce toxicity with another drug is one useful strategy for the treatment of AML. Actinomycetes are the well known sources of antibiotics and bioactive molecules. Previously, we isolated nargenicin from the culture broth of an actinomycete isolate, Nocardia sp. CS682. In this study, we evaluated the effects of nargenicin on cellular differentiation in a human myeloid leukemia HL-60 cell system. Nargenicin inhibited cell proliferation and induced HL-60 cell differentiation when administered in combination with 1,25-(OH)2D3 or ATRA. In addition, western blot analyses and kinase inhibitor studies demonstrated that nargenicin primarily enhanced leukemia cell differentiation via PKCβ1/MAPK pathways. The results of this study indicate that nargenicin has the ability to induce differentiation and suggest that it may be useful for the treatment of neoplastic diseases.

KW - 1,25-Dihydroxyvitamin D

KW - All-trans retinoic acid

KW - Cell differentiation

KW - Mitogen-activated protein kinase

KW - Nargenicin

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=64249148822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249148822&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.03.004

DO - 10.1016/j.bcp.2009.03.004

M3 - Article

C2 - 19428323

AN - SCOPUS:64249148822

VL - 77

SP - 1694

EP - 1701

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -